Relmada Therapeutics, Inc. RLMD Deferred Tax Assets Stock Appreciation Rights
Deferred Tax Assets Stock Appreciation Rights at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept rlmd:DeferredTaxAssetsStockAppreciationRights.
The official record: Relmada Therapeutics, Inc.’s 10-K, filed March 19, 2026, on SEC EDGAR. View the filing →
Ask your AI about Relmada Therapeutics, Inc.'s deferred tax assets stock appreciation rights.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Relmada Therapeutics, Inc.'s deferred tax assets stock appreciation rights?
- Relmada Therapeutics, Inc. (RLMD) reported deferred tax assets stock appreciation rights of $231K in Q4 2025.
- What does deferred tax assets stock appreciation rights mean?
- This metric quantifies the deferred tax assets attributable to stock appreciation rights (SARs) issued as part of employee compensation. It reflects the future tax deductions anticipated when these rights are settled, based on the difference between the grant price and the market value at the time of exercise. Tracking this asset helps investors understand the tax implications of the company's long-term incentive structures.